Samsung Bioepis Initiates Phase 3 Clinical Trial For SB15, Proposed Biosimilar To Eylea (aflibercept)

Samsung Bioepis Co., Ltd. today announced the initiation of Phase 3 clinical trial for SB15, the company's proposed biosimilar referencing Eylea (aflibercept). The Phase 3 clinical trial for SB15 (aflibercept) is a randomised, double-masked, parallel group, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB15 and Eylea in 446 patients with neovascular age-related macular degeneration. For more information, please visit clinicaltrials.gov (NCT #04450329).

Samsung Bioepis has two ophthalmology biosimilar candidates in clinical development, SB11 (ranibizumab) and SB15 (aflibercept). The company has recently announced 24-week interim results from a Phase 3 clinical trial for SB11.

About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology and hematology. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, visit www.samsungbioepis.com.